logo-loader
Energy
Ophir Energy Plc

Ophir Energy dealt US$300mln blow as Fortuna licence isn't extended

"It is disappointing that the ministry has decided not to extend the licence, despite the amount of effort and cost dedicated to the delivery of the project and especially as we were still talking to highly credible potential co-investors"

oil and gas operations
Ophir has been in talks over a potential sale of the company

Takeover target Ophir Energy Plc (LON:OPHR) has revealed it is to suffer a further US$300mln blow in connection to the stalled Fortuna gas project.

Ophir, in a statement, told investors that it has been informed by the Equatorial Guinea authorities that the licence covering Fortuna won’t be extended, following expiry on 31 December 2018.

It means the Ophir will record an additional US$300mln non-cash impairment.

READ: Ophir soars on cash takeover talks

The company, which recently announced it was holding discussions with Indonesian firm Medco over a possible cash offer for Ophir’s entire share capital, and, today, it noted that the talks have taken place “in the shared knowledge that there were a number of potential outcomes with respect to our Fortuna asset”.

Talks with Medco continue, Ophir said

"It is disappointing that the ministry has decided not to extend the licence, despite the amount of effort and cost dedicated to the delivery of the project and especially as we were still talking to highly credible potential co-investors,” said Alan Booth, Ophir interim chief executive.

“Nevertheless, we will continue to work constructively with the authorities in Equatorial Guinea.

Booth added: “Looking ahead, the group's cash flow, capital commitments and growth prospects will be focused in Southeast Asia, where we have built a robust operating platform capable of delivering value to shareholders."

Quick facts: Ophir Energy Plc

Price: £0.00

Market: LSE
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan 'driving research for novel drug development for rare diseases'

Proactive London sits down with Open Orphan PLC's (LON:ORPH) chief commercial officer Maurice Treacy. Treacy discusses how he became involved with Open Orphan and his ambitions for the firm's health data initiative. ''Many rare diseases aren't known or badly diagnosed ... but rare isn't...

18 hours, 39 minutes ago

2 min read